Livogrid 500 Tablet contains Levetiracetam 500mg, an antiepileptic medication primarily indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, which is believed to inhibit burst firing and reduce seizure activity. Livogrid 500 is used as monotherapy or adjunctive therapy in adults and pediatric patients aged one month and older. The tablet formulation offers convenient dosing and reliable bioavailability. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation, which are generally mild to moderate and transient. Dose adjustments may be necessary in patients with renal impairment due to renal excretion of the drug. Livogrid 500 should be administered under medical supervision with gradual dose titration to minimize adverse effects. It is contraindicated in patients with known hypersensitivity to Levetiracetam or any excipients. Caution is advised when used concomitantly with other central nervous system depressants. Regular monitoring of clinical response and tolerability is recommended to optimize therapeutic outcomes and ensure patient safety.